ReviewSeminars in reproductive medicine2010
Role of progesterone in endometrial cancer.
Review in Seminars in reproductive medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 3 syntheses or guidelines pooled it, 214 citations in OpenAlex.
- Male-origin microchimerism and risk of cancer: a systematic review and meta‑analysis.BMC cancer · 2025Pooled it
- The influence of dietary vegetables and fruits on endometrial cancer risk: a meta-analysis of observational studies.European journal of clinical nutrition · 2023Pooled it
- Assessing Post-Treatment Pathologic Tumor Response in Female Genital Tract Carcinomas: An Update.Frontiers in oncology · 2022Pooled it
- Exploring the Possible Role of Endometriosis-Associated Dysbiosis in Endometrial Carcinogenesis.Medicina (Kaunas, Lithuania) · 2026Review
- Induction of puberty in hypogonadal forms of primary amenorrhoea: current evidence and future perspectives.Endocrine connections · 2026Review
- Ligand-Dependent and -Independent Functions of Activation Function 1 of Progesterone Receptor in Genome-Wide Gene Regulation and in Cell Proliferation and Apoptosis of Breast Cancer Cells.International journal of molecular sciences · 2026Article
- CRL4International journal of biological sciences · 2026Article
- Long-term control for > 9 years with megestrol acetate-letrozole: metastatic endometrioid carcinoma case report.Frontiers in oncology · 2026Article
- Endometrial Hyperplasia: Current Insights into Epidemiology, Risk Factors, and Clinical Management.Cancers · 2025Review
- The role of the microbiome in endometrial carcinoma: Pathogenesis, biomarkers, and therapeutic prospects.The journal of obstetrics and gynaecology research · 2025Review
- Review
- Endometrial thickness among BRCA mutation carriers undergoing prophylactic oophorectomy.Familial cancer · 2025Article
- Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer.Cancers · 2025Article
- IKBKE modulates autophagy and progestin resistance in endometrial cancer.Frontiers in oncology · 2025Article
- Association of Pregnancy Complications with Endometrial or Ovarian or Breast Cancer: A Case Control Study.Medicina (Kaunas, Lithuania) · 2024Article
- Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer.Current oncology reports · 2024Review
- Article
- Phosphorylation of IDH1 Facilitates Progestin Resistance in Endometrial Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Stromal Pbrm1 mediates chromatin remodeling necessary for embryo implantation in the mouse uterus.The Journal of clinical investigation · 2024Article
- Review
58 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Progesterone is a key hormone in the endometrium that opposes estrogen-driven growth. Insufficient progesterone will result in unopposed estrogen action that could lead to the development of endometrial hyperplasia and adenocarcinoma. Although these endometrial neoplasias can regress in response to progestin treatment, this does not occur in all instances. To understand this resistance to progesterone and to improve on existing hormonal therapies, it is imperative that the molecular mechanisms of progesterone action through its receptor be deciphered in endometrial cancer. This review highlights what is known thus far regarding the efficacy of progestin therapy in the clinic and the role of progesterone in endometrial cancer cell behavior and gene regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.